Tenet Healthcare Corporation is a diversified healthcare services company operating through two reporting segments: Hospital Operations and Ambulatory Care. The Hospital Operations segment comprises 50 acute care and specialty hospitals, a network of employed physicians, and 132 outpatient facilities, including urgent care centers, imaging centers, off-campus emergency departments, and micro-hospitals. Key hospital brands include Abrazo, Baptist Medical Center, The Hospitals of Providence, MetroWest Medical Center, and Children’s Hospital of Michigan. This segment also includes Conifer Health Solutions, which provides revenue cycle management and value-based care services to hospitals, health systems, and physician practices. The Ambulatory Care segment consists of USPI Holding Company, which holds ownership interests in 533 ambulatory surgery centers and 26 surgical hospitals. Tenet serves patients in urban and suburban communities across eight U.S. states, with significant concentrations in Arizona and Texas. The company partners with NextCare for urgent care center management and previously held a joint venture with John Muir Health for San Ramon Regional Medical Center. Services range from acute and tertiary care, including cardiothoracic surgery and neonatal intensive care, to pediatric quaternary care such as heart, kidney, and liver transplants.

Summarised from the company's own disclosures, fiscal year ended Feb 2026

Industry Medical Care Facilities Homepage tenethealth.com
Sector Healthcare IR page investor.tenethealth.com
Tags
acute care, ambulatory surgery, urgent care, revenue cycle management, value-based care, pediatric care, trauma services, cardiothoracic surgery, neonatal intensive care, imaging services, Conifer Health Solutions, USPI Holding Company, Abrazo Arizona Heart Hospital, Abrazo Arrowhead Campus, Abrazo Central Campus, Abrazo Scottsdale Campus, Abrazo West Campus, Holy Cross Hospital, St. Joseph’s Hospital, St. Mary’s Hospital, Desert Regional Medical Center, Doctors Hospital of Manteca, Doctors Medical Center, Emanuel Medical Center, Hi-Desert Medical Center, John F. Kennedy Memorial Hospital, San Ramon Regional Medical Center, Delray Medical Center, Florida Coast Medical Center, Good Samaritan Medical Center, Palm Beach Gardens Medical Center, St. Mary’s Medical Center, West Boca Medical Center, MetroWest Medical Center, Saint Vincent Hospital, Children’s Hospital of Michigan, Detroit Receiving Hospital, Harper University Hospital, Huron Valley-Sinai Hospital, Hutzel Women’s Hospital, Rehabilitation Institute of Michigan, Sinai-Grace Hospital, Piedmont Medical Center, Saint Francis Hospital, Baptist Medical Center, The Hospitals of Providence, Mission Trail Baptist Hospital, Nacogdoches Medical Center, North Central Baptist Hospital, Northeast Baptist Hospital, Resolute Baptist Hospital, St. Luke’s Baptist Hospital, Valley Baptist Medical Center, Westover Hills Baptist Hospital, NextCare, John Muir Health, CommonSpirit Health
Press page —

Metrics

Valuation  
Market cap $ 23.319B
Market cap (USD) $ 23.319B
P/E 8.50
PEG 0.17
P/BV 4.28
P/S 1.05
P/OCF 5.50
P/FCF 7.01
Dividend yield —
Turnover / mcap —
Returns  
ROE 56.4%
ROI 13.6%
ROIC 17.1%
Profit margin 11.1%
Growth  
Revenue growing Yes
Profits growing No
Revenue up 3y Yes
Revenue up 5y No
Earnings growth 3y (net profit CAGR) 50.7%
Quality  
Profitable Yes
Margin expanding No
Buying back stock Yes
Diluting (TTM) No
Debt/Equity 312.1%
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 31
Quality score 44.4%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010 FY 2009 FY 2008 FY 2007 FY 2006 FY 2005 FY 2004 FY 2002 FY 2001 FY 2000
Revenue 21.31B 20.665B 20.548B 19.174B 19.485B 17.64B 18.479B 18.313B — — — — — — — — 9.014B 8.663B 8.852B 8.701B 9.614B — 13.913B 12.053B 11.414B
Net profit 2.367B 4.064B 1.311B 1.001B 1.476B 768M 154M 466M -320M 176M 78M 76M -104M 133M 94M 1.119B 197M 25M -89M -803M -724M — 785M 643M 302M
Free cash flow 2.53B 1.116B 1.623B 321M 910M 2.867B 563M 432M 493M -317M 184M -246M -102M — — — 28M -244M -336M -1.093B — — 1.426B 1.217B 250M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010 FY 2009 FY 2008 FY 2007 FY 2006 FY 2005 FY 2004 FY 2002 FY 2001 FY 2000
Share price 198.72 126.23 75.57 48.79 81.69 39.93 38.03 17.14 15.16 14.84 30.3 50.67 42.12 32.47 5.13 4.5 — 2.04 4.35 7.13 — — — — —
Price performance 12m 0.57 0.67 0.55 -0.4 1.05 0.05 1.22 0.13 0.02 -0.51 -0.4 0.2 0.3 5.33 0.14 — — -0.53 -0.39 — — — — — —

Filed figures

Figure Dec 2016 Dec 2017 Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (USD) 2.9B 2.62B 2.6B 2.74B 2.69B 2.77B 2.94B 2.91B 2.54B 2.57B
↳ YoY growth +7.1% -9.7% -0.8% +5.7% -1.9% +3.0% +6.2% -1.0% -13.0% +1.1%
↳ 5y CAGR +17.8% +14.2% +5.0% +2.7% -0.1% -0.9% +2.4% +2.3% -1.6% -0.9%
Borrowings, current (USD) 191M 146M 182M 171M 145M 135M 145M 120M 92M 79M
Borrowings, non-current (USD) 15.1B 14.8B 14.6B 14.6B 15.6B 15.5B 14.9B 14.9B 13.1B 13.1B
Lease liabilities (USD) — — 862M 1.34B 1.46B 1.41B 1.52B 1.42B 1.6B 1.71B
Cash and deposits (USD) 716M 611M 411M 262M 2.45B 2.36B 858M 1.23B 3.02B 2.88B
Intangible assets (USD) 1.85B 1.77B 1.73B 1.6B 1.6B 1.5B 1.42B 1.37B 1.4B 1.35B
Right-of-use assets (USD) — — 822M 912M 1.06B 1B 1.13B 1.08B 1.04B 1.13B
Net debt (borrowings + leases - cash) (USD) 14.5B 14.3B 14.4B 15.8B 14.7B 14.7B 15.7B 15.2B 11.8B 12B
Cash flow detail
Operating cash flow (USD) 558M 1.2B 1.05B 1.23B 3.41B 1.57B 1.08B 2.37B 2.05B 3.54B
Purchases of property, plant and equipment (USD) -875M -707M -617M -670M -540M -658M -762M -751M -931M -1.01B
Change in receivables (cash effect) (USD) -1.6B -1.45B -134M -247M 195M -197M -140M -29M 245M 20M
Change in payables (cash effect) (USD) -51M -10M -152M 36M 1.3B -584M -898M 215M -30M 209M
Share buybacks (cash effect) (USD) 0.00 0.00 — — 0.00 0.00 -250M -200M -672M -1.39B
Interest paid (cash effect) (USD) -932M -939M -976M -946M -962M -937M -848M -882M -851M -865M
Income taxes paid (cash effect) (USD) -33M -56M -25M -12M -12M -92M -161M -243M -1.27B -450M
Share-based compensation (USD) 68M 59M 46M 42M 44M 56M 56M 66M 67M 104M
Operating cash flow before change in receivables (USD) 2.16B 2.65B 1.18B 1.48B 3.21B 1.77B 1.22B 2.4B 1.8B 3.52B
Free cash flow (OCF - PPE - intangibles) (USD) -317M 493M 432M 563M 2.87B 910M 321M 1.62B 1.12B 2.53B
Income detail
Total comprehensive income (USD) 82M -266M 490M 120M 744M 1.52B 1.05B 1.31B 4.07B 2.37B
Comprehensive income to owners (USD) -286M -650M 135M -266M 375M 962M 463M 611M 3.2B 1.41B
Reported Feb 26, 2018 Feb 26, 2018 Apr 29, 2019 Feb 24, 2020 Feb 21, 2023 Feb 21, 2023 Feb 21, 2023 Feb 16, 2024 Feb 18, 2025 Feb 17, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

October 29, 2026

  • Net income available to common shareholders in third quarter 2026 was $1.000 billion, or $12.41 per diluted share compared to $342 million, or $3.86 in third quarter 2025

  • Adjusted diluted earnings per share1 increased 79.5% to $6.64 in third quarter 2026 compared to $3.70 in third quarter 2025

  • Third quarter 2026 Consolidated Adjusted EBITDA1 increased 23.3% over third quarter 2025 to $1.355 billion; Third quarter 2026 Adjusted EBITDA margin was 24.1%

  • Third quarter 2026 Ambulatory Care Adjusted EBITDA of $537 million increased 9.1% over third quarter 2025

  • FY 2026 Adjusted EBITDA Outlook is now expected to be in the range of $5.05 billion to $5.20 billion, a $195 million increase at the midpoint of the range; FY 2026 Adjusted Free Cash Flow outlook now expected to be in the range of $2.825 billion to $3.125 billion, a $100 million increase

DALLAS--(BUSINESS WIRE)-- Tenet Healthcare Corporation (Tenet) (NYSE: THC) today announced its results for the quarter ended September 30, 2026.

"Our outperformance in the third quarter of 2026 was driven by sustained strength in same-store revenue growth and effective expense management," said Saum Sutaria, M.D., Chairman and Chief Executive Officer of Tenet. "Our focus on patient-centered care, support for physician partners, technology-enabled growth and operating initiatives continue to deliver strong margins and free cash flow."

Tenet’s results for third quarter 2026 versus third quarter 2025 are as follows:

Three Months Ended September 30, Nine Months Ended September 30,
($ in millions, except per share results) 2026 2025 2026 2025
Net operating revenues7 $5,631 $5,289 $16,627 $15,783
Net income available to Tenet common shareholders $1,000 $342 $2,528 $1,036
Net income available to Tenet common shareholders per diluted share $12.41 $3.86 $30.08 $11.28
Adjusted EBITDA1 $1,355 $1,099 $3,821 $3,383
Adjusted diluted earnings per share1 $6.64 $3.70 $17.50 $12.10
  • Net income available to the Company’s common shareholders in third quarter 2026 was $1.000 billion, or $12.41 per diluted share, versus $342 million, or $3.86 per diluted share, in third quarter 2025.

  • The Company had previously entered into certain agreements with CommonSpirit Health, related to Conifer Health Solutions, LLC ("Conifer"), whereby the parties agreed, in part, to the early conclusion and transition of our revenue cycle management services by December 31, 2026, (collectively, the "RCM Agreements").

  • The transition of certain revenue cycle management services under the RCM Agreements occurred during the third quarter of 2026 and will be substantially complete by October 30, 2026. As a result of this revised timeline, during the three months ended September 30, 2026, we recognized cumulative catch-up adjustments that increased revenue from contract termination by $233 million and net operating revenues by $97 million. These are timing-related adjustments and as such, do not impact total or full year 2026 expectations for revenue from contract termination or net operating revenues associated with the RCM Agreements.

  • In addition, we recognized a benefit of approximately $50 million during the three months ended September 30, 2026 due to various transition activities, including efficiencies from the revised timeline described above. This, combined with the $97 million timing-related adjustment to net operating revenue mentioned above, resulted in a favorable net impact to Adjusted EBITDA of $147 million in the third quarter of 2026.

  • Adjusted EBITDA 1 was $1.355 billion in third quarter 2026 compared to $1.099 billion in third quarter 2025, reflecting strong same facility revenue growth and disciplined expense management partially offset by unfavorable payer mix due to lower exchange admissions. Results also include the $147 million favorable net impact described above.

Balance Sheet and Cash Flows

  • Net cash flows provided by operating activities for the nine months ended September 30, 2026 were $3.507 billion versus $2.809 billion for the nine months ended September 30, 2025.

  • The Company generated adjusted free cash flow 1 of $2.524 billion for the nine months ended September 30, 2026 versus $2.247 billion for the nine months ended September 30, 2025.

  • In the three months ended September 30, 2026, the Company repurchased 970,000 shares of common stock for $255 million. In the nine months ended September 30, 2026, the Company repurchased 7.99 million shares of common stock for $1.615 billion.

  • In September 2026, the Company completed a private placement of $2.0 billion in aggregate principal amount of newly issued 6.250% senior notes maturing in 2034. The Company used the net proceeds from the sale of the notes, after payment of fees and expenses, to finance, together with cash on hand, the redemption of all $1.5 billion aggregate principal amount then outstanding of its 5.125% senior secured first lien notes due in 2027 and the partial redemption of $500 million outstanding of its 6.125% senior notes due in 2028.

  • The Company’s ratio of net debt to Adjusted EBITDA 1 was 2.11x at September 30, 2026 compared to 2.33x at June 30, 2026 and 2.25x at December 31, 2025.

Ambulatory Care (Ambulatory) Segment

Tenet’s Ambulatory business segment is comprised of the operations of United Surgical Partners International (USPI). As of September 30, 2026, USPI had interests in 535 ambulatory surgery centers (406 consolidated) and 25 surgical hospitals (seven consolidated) in 37 states.
Three Months Ended September 30, Nine Months Ended September 30,
Ambulatory segment results ($ in millions) 2026 2025 2026 2025
Revenues
Net operating revenues $1,371 $1,275 $4,079 $3,739
Same-facility system-wide net patient service revenues2 $2,224 $2,129 $6,515 $6,196
Changes versus the Prior-Year Period
Same-facility system-wide net patient service revenues 4.5 % 8.3 % 5.1 % 7.5 %
Same-facility system-wide net patient service revenue per case 6.1 % 6.1 % 6.0 % 7.7 %
Same-facility system-wide surgical cases2 (1.5) % 2.1 % (0.8) % (0.2) %
Same-facility system-wide surgical cases on same-business day basis2 (1.5) % 2.1 % (0.8) % 0.4 %
Adjusted EBITDA, Margins and NCI
Adjusted EBITDA $537 $492 $1,563 $1,446
Adjusted EBITDA margin 39.2 % 38.6 % 38.3 % 38.7 %
Adjusted EBITDA less NCI $327 $292 $948 $874
  • Third quarter 2026 net operating revenues increased 7.5% compared to third quarter 2025 driven by strong growth in consolidated same-facility net patient service revenues, acquisitions of facilities, and increased service lines.

  • Surgical business same-facility system-wide net patient service revenues increased 4.5% in third quarter 2026 compared to third quarter 2025, with cases down 1.5% and net revenue per case up 6.1%. Net revenue per case growth was driven by higher acuity and favorable service mix.

  • Third quarter 2026 Adjusted EBITDA increased 9.1% compared to third quarter 2025, due to strong growth in same-facility net patient service revenues, disciplined expense management, and contributions from acquisitions.

Hospital Operations and Services (Hospital) Segment

Tenet’s Hospital business segment is primarily comprised of acute care and specialty hospitals, imaging centers, ancillary outpatient facilities, micro-hospitals and physician practices. It also provides comprehensive end-to-end and focused point services, including hospital and physician revenue cycle management, patient communications and engagement support and value-based care solutions.
Three Months Ended September 30, Nine Months Ended September 30,
Hospital segment results ($ in millions) 2026 2025 2026 2025
Revenues
Net operating revenues7 $4,260 $4,014 $12,548 $12,044
Same-hospital net patient service revenues3 $3,571 $3,453 $10,678 $10,385
Same-Hospital Volume Changes versus the Prior-Year Period
Admissions 2.8 % 1.5 % 1.8 % 2.5 %
Adjusted admissions4 3.2 % 1.4 % 2.1 % 1.6 %
Outpatient visits (including outpatient ER visits) 0.1 % (1.5) % (0.9) % (1.4) %
Emergency Room visits (inpatient and outpatient) 4.0 % (2.0) % 0.9 % (1.8) %
Hospital surgeries (1.1) % 0.7 % (0.9) % (0.8) %
Adjusted EBITDA
Adjusted EBITDA $818 $607 $2,258 $1,937
Adjusted EBITDA margin 19.2 % 15.1 % 18.0 % 16.1 %
  • Third quarter 2026 net operating revenues increased 6.1% from third quarter 2025 driven by an increase in adjusted admissions as well as continued pricing strength, partially offset by unfavorable payer mix due to lower exchange admissions. In addition, third quarter 2026 net operating revenues include a timing-related benefit of $97 million associated with the RCM Agreements as described on page 2.

  • Same-hospital net patient service revenue per adjusted admission increased 0.2% year-over-year for third quarter 2026 primarily due to strength in commercial employer net patient revenues offset by unfavorable payer mix related to lower exchange admissions.

  • Adjusted EBITDA in third quarter 2026 was $818 million compared to $607 million in third quarter 2025, reflecting strong growth in same-hospital revenue and disciplined expense management, partially offset by unfavorable payer mix due to lower exchange admissions. Results also include the net favorable impact of $147 million from transition activities described on page 2.

  • In the third quarter of 2026, the Hospital segment recognized a $32 million favorable pre-tax impact associated with additional Medicaid supplemental revenues related to prior years. Third quarter 2025 results included a $38 million favorable pre-tax impact for additional Medicaid supplemental revenues related to prior years.

2026 Outlook1

Tenet’s Outlook for full year 2026 (consolidated and by segment) follows. Contract termination revenue recognized from the early conclusion of the RCM Agreements is not included in net operating revenues.

CONSOLIDATED ($ in millions, except per share amounts) FY 2026 Outlook
Net operating revenues7 $22,050 to $22,450
Net income available to Tenet common shareholders $2,973 to $3,078
Adjusted EBITDA $5,050 to $5,200
Adjusted EBITDA margin 22.9% to 23.2%
Diluted income per common share $35.82 to $37.08
Adjusted net income $1,830 to $1,910
Adjusted diluted earnings per share $22.05 to $23.01
Equity in earnings of unconsolidated affiliates $265 to $275
Depreciation and amortization $865 to $915
Interest expense $815 to $825
Income tax expense5 $1,135 to $1,170
Net income available to NCI $910 to $960
Weighted average diluted common shares ~83 million
Net cash provided by operating activities $3,885 to $4,315
Adjusted net cash provided by operating activities $3,525 to $3,925
Capital expenditures $700 to $800
Free cash flow $3,185 to $3,515
Adjusted free cash flow $2,825 to $3,125
NCI cash distributions $900 to $970
Ambulatory Segment ($ in millions) FY 2026 Outlook
Net operating revenues $5,530 to $5,670
Adjusted EBITDA $2,160 to $2,220
NCI $865 to $895
Adjusted EBITDA less NCI $1,295 to $1,325
Changes versus prior year6:
Same-facility system-wide revenues Up 3.0% to 6.0%
Hospital Segment ($ in millions) FY 2026 Outlook
Net operating revenues7 $16,520 to $16,780
Adjusted EBITDA $2,890 to $2,980
NCI $45 to $65
Changes versus prior year6:
Inpatient admissions Up 1.0% to 2.0%
Adjusted admissions Up 1.0% to 2.0%

Management’s Webcast Discussion of Results

Tenet management will discuss the Company’s third quarter 2026 results in a webcast scheduled for 10:00 a.m. Eastern Time (9:00 a.m. Central Time) on October 29, 2026. Investors can access the webcast through the Company’s website at www.tenethealth.com/investors .

The slide presentation associated with the webcast referenced above, a copy of this earnings press release, and a related supplemental financial disclosures document will be available on the Company’s Investor Relations website on October 29, 2026.

Cautionary Statement

This release contains “forward-looking statements” - that is, statements that relate to future, not past, events. In this context, forward-looking statements often address the Company’s expected future business and financial performance and financial condition, and often contain words such as “expect,” “anticipate,” “assume,” “believe,” “budget,” “estimate,” “forecast,” “intend,” “plan,” “predict,” “project,” “seek,” “see,” “target,” or “will.” Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Particular uncertainties that could cause the Company’s actual results to be materially different than those expressed in the Company’s forward-looking statements include, but are not limited to the factors disclosed under “Forward-Looking Statements” and “Risk Factors” in our Form 10-K for the year ended December 31, 2025 and other filings with the Securities and Exchange Commission.

Footnotes

  1. Tables and discussions throughout this earnings release include certain financial measures, including those related to our full year 2026 Outlook, that are not in accordance with accounting principles generally accepted in the United States of America (GAAP). Reconciliations of GAAP measures to the Adjusted (non-GAAP) measures used are detailed in Tables #1-6 included at the end of this earnings release. Management’s reasoning for the use of these non-GAAP measures and descriptions of the various non-GAAP measures are included in the Non-GAAP Financial Measures section of this earnings release.
  2. Same-facility system-wide revenues and statistical information include the results of the facilities in which the Ambulatory segment has an investment that are not consolidated by Tenet. To help analyze the segment’s results of operations, management uses system-wide measures, which include revenues and cases of both consolidated and unconsolidated facilities.
  3. For 2026, same-hospital revenues and statistical data include those for hospitals and hospital-affiliated outpatient centers operated by the Company’s Hospital segment continuously from January 1, 2025 through September 30, 2026. Amounts associated with physician practices are excluded.
  4. Adjusted admissions represent actual patient admissions adjusted to include outpatient services provided by facilities in our Hospital segment by multiplying actual patient admissions by the sum of gross inpatient revenues and outpatient revenues, then dividing that result by gross inpatient revenues.
  5. Income tax expense is calculated by multiplying 24% (the federal corporate tax rate of 21% plus an estimate of state taxes) by the sum of: pretax income less NCI expense plus permanent differences, and non-deductible interest expense.
  6. Change versus prior year is presented on a same-facility system-wide basis for USPI Ambulatory surgical cases and on a same-hospital basis for hospital statistics.
  7. Contract termination revenue recognized from the early conclusion of the RCM Agreements is not included in net operating revenues.

About Tenet Healthcare

Tenet Healthcare Corporation (NYSE: THC) is a diversified healthcare services company headquartered in Dallas. Our care delivery network includes United Surgical Partners International, the largest ambulatory platform in the country, which operates ambulatory surgery centers and surgical hospitals. We also operate a national portfolio of acute care and specialty hospitals, other outpatient facilities, a network of leading employed physicians and a global business center in Manila, Philippines. Our Conifer Health Solutions subsidiary provides revenue cycle management and value-based care services to hospitals, health systems, physician practices, employers and other clients. Across the Tenet enterprise, we are united by our mission to deliver quality, compassionate care in the communities we serve. For more information, please visit www.tenethealth.com .

Non-GAAP Financial Measures

The Company believes the non-GAAP measures described below are useful to investors and analysts because they present additional information on the Company’s financial performance. Investors, analysts, Company management and the Company’s Board of Directors utilize these non-GAAP measures, in addition to GAAP measures, to track the Company’s financial and operating performance and compare the Company’s performance to its peer companies, which use similar non-GAAP financial measures in their presentations and earnings releases. The Human Resources Committee of the Company’s Board of Directors also uses certain of these measures to evaluate management’s performance for the purpose of determining incentive compensation. Additional information regarding the purpose and utility of specific non-GAAP measures used in this release is set forth below.

  • Adjusted EBITDA is defined by the Company as net income available (loss attributable) to Tenet common shareholders before (1) the cumulative effect of changes in accounting principles, (2) net loss attributable (income available) to noncontrolling interests, (3) income (loss) from discontinued operations, net of tax, (4) income tax benefit (expense), (5) gain (loss) from early extinguishment of debt, (6) other non-operating income (expense), net, (7) interest expense, (8) litigation and investigation benefit (costs), net of insurance recoveries, (9) net gains (losses) on sales, consolidation and deconsolidation of facilities, (10) impairment and restructuring charges and acquisition-related costs, (11) depreciation and amortization, (12) income (loss) from divested and closed businesses (i.e., health plan businesses) and (13) revenue from contract termination. Revenue from contract termination represents the present value of the $1.9 billion of consideration related to the early termination of Conifer’s revenue cycle services agreement with CommonSpirit (as further described in the Company’s Form 8-K dated February 2, 2026), net of amortization of an associated contract asset. Litigation and investigation benefit (costs) excluded do not include ordinary course of business malpractice and other litigation and related expenses.

  • Adjusted diluted earnings (loss) per share is defined by the Company as Adjusted net income available (loss attributable) to Tenet common shareholders, divided by the weighted average diluted shares outstanding in the reporting period.

  • Adjusted net income available (loss attributable) to Tenet common shareholders is defined by the Company as net income available (loss attributable) to Tenet common shareholders before (1) income (loss) from discontinued operations, net of tax, (2) gain (loss) from early extinguishment of debt, (3) litigation and investigation benefit (costs), net of insurance recoveries, (4) net gains (losses) on sales, consolidation and deconsolidation of facilities, (5) impairment and restructuring charges and acquisition-related costs, (6) income (loss) from divested and closed businesses (i.e., health plan businesses), (7) revenue from contract termination and (8) the associated impact of these items on taxes and noncontrolling interests. Revenue from contract termination represents the present value of the $1.9 billion of consideration related to the early termination of Conifer’s revenue cycle services agreement with CommonSpirit (as further described in the Company’s Form 8-K dated February 2, 2026), net of amortization of an associated contract asset. Litigation and investigation benefit (costs) excluded do not include ordinary course of business malpractice and other litigation and related expenses.

  • Free Cash Flow is defined by the Company as (1) net cash provided by (used in) operating activities, less (2) purchases of property and equipment.

  • Adjusted Free Cash Flow is defined by the Company as (1) Adjusted net cash provided by (used in) operating activities, less (2) purchases of property and equipment.

  • Adjusted net cash provided by (used in) operating activities is defined by the Company as cash provided by (used in) operating activities prior to (1) payments for restructuring charges, acquisition-related costs and litigation costs and settlements, (2) net cash provided by (used in) operating activities from discontinued operations and (3) cash received for contract termination defined above.

The Company believes that Adjusted EBITDA is a useful measure, in part, because certain investors and analysts use both historical and projected Adjusted EBITDA, in addition to other GAAP and non-GAAP measures, as factors in determining the estimated fair value of shares of the Company’s common stock. Company management also regularly reviews the Adjusted EBITDA performance for each operating segment. The Company does not use Adjusted EBITDA to measure liquidity, but instead to measure operating performance.

The Company uses, and believes investors use, Free Cash Flow and Adjusted Free Cash Flow as supplemental non-GAAP measures to analyze cash flows generated from the Company’s operations. The Company believes these measures are useful to investors in evaluating its ability to fund distributions paid to noncontrolling interests or for acquisitions, purchasing equity interests in joint ventures or repaying debt.

These non-GAAP measures may not be comparable to similarly titled measures reported by other companies. Because these measures exclude many items that are included in the Company’s financial statements, they do not provide a complete measure of the Company’s operating performance. For example, the Company’s definitions of Free Cash Flow and Adjusted Free Cash Flow do not include other important uses of cash including (1) cash used to purchase businesses or joint venture interests, or (2) any items that are classified as Cash Flows from Financing Activities on the Company’s Consolidated Statement of Cash Flows, including items such as (i) cash used to repay borrowings, or (ii) distributions paid to noncontrolling interests. Accordingly, investors are encouraged to use GAAP measures when evaluating the Company’s financial performance.

See corresponding reconciliations of the non-GAAP financial measures referred to above to the most comparable GAAP financial measures in Tables #1 - 6 below.

TENET HEALTHCARE CORPORATIONCONSOLIDATED STATEMENTS OF OPERATIONS(Unaudited)
(Dollars in millions, except per share amounts) Three Months Ended September 30,
2026 % 2025 % Change
Net operating revenues $ 5,631 100.0 % $ 5,289 100.0 % 6.5 %
Revenue from contract termination 646 11.5 % — — % 100.0 %
Equity in earnings of unconsolidated affiliates 64 1.1 % 64 1.2 % — %
Operating expenses:
Salaries, wages and benefits 2,173 38.6 % 2,204 41.7 % (1.4 )%
Supplies 983 17.5 % 931 17.6 % 5.6 %
Other operating expenses, net 1,184 21.0 % 1,119 21.2 % 5.8 %
Depreciation and amortization 217 3.8 % 218 4.1 %
Impairment and restructuring charges, and acquisition-related costs 37 0.7 % 23 0.4 %
Litigation and investigation costs (benefit) 6 0.1 % (11 ) (0.2 )%
Net gains on sales, consolidation and deconsolidation of facilities (9 ) (0.2 )% (20 ) (0.4 )%
Operating income 1,750 31.1 % 889 16.8 %
Interest expense (203 ) (206 )
Other non-operating income, net 37 29
Loss from early extinguishment of debt (5 ) —
Income before income taxes 1,579 712
Income tax expense (360 ) (133 )
Net income 1,219 579
Less: Net income available to noncontrolling interests 219 237
Net income available to Tenet Healthcare Corporation common shareholders $ 1,000 $ 342
Earnings per share available to Tenet Healthcare Corporation common shareholders:
Basic $ 12.48 $ 3.89
Diluted $ 12.41 $ 3.86
Weighted average shares and dilutive securities outstanding (in thousands):
Basic 80,134 87,951
Diluted 80,600 88,610
TENET HEALTHCARE CORPORATIONCONSOLIDATED STATEMENTS OF OPERATIONS(Unaudited)
(Dollars in millions, except per share amounts) Nine Months Ended September 30,
2026 % 2025 % Change
Net operating revenues $ 16,627 100.0 % $ 15,783 100.0 % 5.3 %
Revenue from contract termination 1,472 8.9 % — — % 100.0 %
Equity in earnings of unconsolidated affiliates 180 1.1 % 181 1.1 % (0.6 )%
Operating expenses:
Salaries, wages and benefits 6,578 39.6 % 6,483 41.1 % 1.5 %
Supplies 2,928 17.6 % 2,770 17.6 % 5.7 %
Other operating expenses, net 3,480 20.9 % 3,328 21.0 % 4.6 %
Depreciation and amortization 661 4.0 % 632 4.0 %
Impairment and restructuring charges, and acquisition-related costs 92 0.6 % 66 0.4 %
Litigation and investigation costs 36 0.2 % 34 0.2 %
Net gains on sales, consolidation and deconsolidation of facilities (43 ) (0.2 )% (4 ) — %
Operating income 4,547 27.3 % 2,655 16.8 %
Interest expense (612 ) (616 )
Other non-operating income, net 121 80
Loss from early extinguishment of debt (5 ) —
Income before income taxes 4,051 2,119
Income tax expense (881 ) (396 )
Net income 3,170 1,723
Less: Net income available to noncontrolling interests 642 687
Net income available to Tenet Healthcare Corporation common shareholders $ 2,528 $ 1,036
Earnings per share available to Tenet Healthcare Corporation common shareholders:
Basic $ 30.28 $ 11.37
Diluted $ 30.08 $ 11.28
Weighted average shares and dilutive securities outstanding (in thousands):
Basic 83,486 91,109
Diluted 84,053 91,805
TENET HEALTHCARE CORPORATIONCONSOLIDATED BALANCE SHEETS(Unaudited)
(Dollars in millions) September 30, 2026 December 31, 2025
ASSETS
Current assets:
Cash and cash equivalents $ 2,674 $ 2,883
Accounts receivable 2,595 2,565
Inventories of supplies, at cost 340 348
Assets held for sale 62 62
Other current assets 2,757 1,991
Total current assets 8,428 7,849
Investments and other assets 3,958 2,883
Deferred income taxes 49 84
Property and equipment, at cost, less accumulated depreciation and amortization 6,290 6,315
Goodwill 11,641 11,198
Other intangible assets, at cost, less accumulated amortization 1,226 1,348
Total assets $ 31,592 $ 29,677
LIABILITIES AND EQUITY
Current liabilities:
Current portion of long-term debt $ 164 $ 79
Accounts payable 1,387 1,360
Accrued compensation and benefits 873 858
Professional and general liability reserves 317 276
Accrued interest payable 213 81
Income tax payable 22 —
Other current liabilities 2,342 1,809
Total current liabilities 5,318 4,463
Long-term debt, net of current portion 13,079 13,092
Professional and general liability reserves 979 951
Defined benefit plan obligations 238 245
Deferred income taxes 529 240
Other long-term liabilities 1,855 1,713
Total liabilities 21,998 20,704
Commitments and contingencies
Redeemable noncontrolling interests in equity of consolidated subsidiaries 2,179 2,956
Equity:
Shareholders’ equity:
Common stock 8 8
Additional paid-in capital 5,236 4,914
Accumulated other comprehensive loss (178 ) (181 )
Retained earnings 6,943 4,415
Common stock in treasury, at cost (6,565 ) (4,936 )
Total shareholders’ equity 5,444 4,220
Noncontrolling interests 1,971 1,797
Total equity 7,415 6,017
Total liabilities and equity $ 31,592 $ 29,677
TENET HEALTHCARE CORPORATIONCONSOLIDATED STATEMENTS OF CASH FLOWS(Unaudited)
Nine Months Ended
September 30,
(Dollars in millions) 2026 2025
Net income $ 3,170 $ 1,723
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization 661 632
Deferred income tax expense 324 51
Stock-based compensation expense 104 79
Impairment and restructuring charges, and acquisition-related costs 92 66
Litigation and investigation costs 36 34
Net gains on sales, consolidation and deconsolidation of facilities (43 ) (4 )
Loss from early extinguishment of debt 5 —
Equity in earnings of unconsolidated affiliates, net of distributions received (11 ) (13 )
Amortization of debt discount and debt issuance costs 16 18
Other items, net (11 ) (5 )
Changes in cash from operating assets and liabilities:
Accounts receivable (11 ) 68
Inventories and other current assets 211 (58 )
Income taxes 63 15
Accounts payable, accrued expenses and other current liabilities (1,042 ) 237
Other long-term liabilities 46 50
Payments for restructuring charges, acquisition-related costs, and litigation costs and settlements (103 ) (84 )
Net cash provided by operating activities 3,507 2,809
Cash flows from investing activities:
Purchases of property and equipment (546 ) (646 )
Purchases of businesses or joint venture interests, net of cash acquired (201 ) (266 )
Proceeds from sales of facilities and other assets 11 18
Proceeds from sales of marketable securities and long-term investments 66 74
Purchases of marketable securities and long-term investments (122 ) (69 )
Other items, net (26 ) 3
Net cash used in investing activities (818 ) (886 )
Cash flows from financing activities:
Repayments of borrowings (2,087 ) (90 )
Proceeds from borrowings 2,041 21
Repurchases of common stock (1,615 ) (1,188 )
Debt issuance costs (22 ) —
Distributions paid to noncontrolling interests (614 ) (585 )
Proceeds from the sale of noncontrolling interests 33 27
Purchases of noncontrolling interests (583 ) (88 )
Repayments of advances from managed care payers — (33 )
Taxes paid related to net share settlement, net of proceeds from shares issued under stock‑based compensation plans (84 ) (47 )
Other items, net 33 16
Net cash used in financing activities (2,898 ) (1,967 )
Net decrease in cash and cash equivalents (209 ) (44 )
Cash and cash equivalents at beginning of period 2,883 3,019
Cash and cash equivalents at end of period $ 2,674 $ 2,975
Supplemental disclosures:
Interest paid, net of capitalized interest $ (464 ) $ (499 )
Income tax payments, net $ (493 ) $ (329 )
TENET HEALTHCARE CORPORATIONSEGMENT REPORTING(Unaudited)
Three Months Ended Nine Months Ended
September 30, September 30,
(Dollars in millions) 2026 2025 2026 2025
Net operating revenues:
Ambulatory Care $ 1,371 $ 1,275 $ 4,079 $ 3,739
Hospital Operations and Services 4,260 4,014 12,548 12,044
Total $ 5,631 $ 5,289 $ 16,627 $ 15,783
Equity in earnings of unconsolidated affiliates:
Ambulatory Care $ 64 $ 63 $ 179 $ 176
Hospital Operations and Services — 1 1 5
Total $ 64 $ 64 $ 180 $ 181
Adjusted EBITDA:
Ambulatory Care $ 537 $ 492 $ 1,563 $ 1,446
Hospital Operations and Services 818 607 2,258 1,937
Total $ 1,355 $ 1,099 $ 3,821 $ 3,383
Adjusted EBITDA margins:
Ambulatory Care 39.2 % 38.6 % 38.3 % 38.7 %
Hospital Operations and Services 19.2 % 15.1 % 18.0 % 16.1 %
Total 24.1 % 20.8 % 23.0 % 21.4 %
Capital expenditures:
Ambulatory Care $ 40 $ 38 $ 110 $ 90
Hospital Operations and Services 158 242 436 556
Total $ 198 $ 280 $ 546 $ 646
TENET HEALTHCARE CORPORATIONAdditional Supplemental Non-GAAP disclosuresTable #1 – Reconciliations of Net Income Available to Tenet Healthcare Corporation Common Shareholders to Adjusted Net Income Available to Common Shareholders(Unaudited)
Three Months Ended Nine Months Ended
September 30, September 30,
(Dollars in millions, except per share amounts) 2026 2025 2026 2025
Net income available to Tenet Healthcare Corporation common shareholders $ 1,000 $ 342 $ 2,528 $ 1,036
Less:
Revenue from contract termination 646 — 1,472 —
Impairment and restructuring charges, and acquisition-related costs (37 ) (23 ) (92 ) (66 )
Litigation and investigation benefit (costs) (6 ) 11 (36 ) (34 )
Net gains on sales, consolidation and deconsolidation of facilities 9 20 43 4
Loss from early extinguishment of debt (5 ) — (5 ) —
Tax and noncontrolling interests impact of above items (142 ) 6 (325 ) 21
Adjusted net income available to common shareholders $ 535 $ 328 $ 1,471 $ 1,111
Diluted earnings per share $ 12.41 $ 3.86 $ 30.08 $ 11.28
Less:
Revenue from contract termination 8.01 — 17.51 —
Impairment and restructuring charges, and acquisition-related costs (0.46 ) (0.26 ) (1.09 ) (0.72 )
Litigation and investigation benefit (costs) (0.07 ) 0.12 (0.43 ) (0.37 )
Net gains on sales, consolidation and deconsolidation of facilities 0.11 0.23 0.51 0.04
Loss from early extinguishment of debt (0.06 ) — (0.06 ) —
Tax and noncontrolling interests impact of above items (1.76 ) 0.07 (3.86 ) 0.23
Adjusted diluted earnings per share $ 6.64 $ 3.70 $ 17.50 $ 12.10
Weighted average basic shares outstanding (in thousands) 80,134 87,951 83,486 91,109
Weighted average dilutive shares outstanding (in thousands) 80,600 88,610 84,053 91,805
TENET HEALTHCARE CORPORATIONAdditional Supplemental Non-GAAP disclosuresTable #2 – Reconciliations of Net Income Available to Tenet Healthcare Corporation Common Shareholders to Adjusted EBITDA(Unaudited)
Three Months Ended Nine Months Ended
September 30, September 30,
(Dollars in millions) 2026 2025 2026 2025
Net income available to Tenet Healthcare Corporation common shareholders $ 1,000 $ 342 $ 2,528 $ 1,036
Less:
Net income available to noncontrolling interests (219 ) (237 ) (642 ) (687 )
Net income 1,219 579 3,170 1,723
Income tax expense (360 ) (133 ) (881 ) (396 )
Loss from early extinguishment of debt (5 ) — (5 ) —
Other non-operating income, net 37 29 121 80
Interest expense (203 ) (206 ) (612 ) (616 )
Operating income 1,750 889 4,547 2,655
Revenue from contract termination 646 — 1,472 —
Depreciation and amortization (217 ) (218 ) (661 ) (632 )
Impairment and restructuring charges, and acquisition-related costs (37 ) (23 ) (92 ) (66 )
Litigation and investigation benefit (costs) (6 ) 11 (36 ) (34 )
Net gains on sales, consolidation and deconsolidation of facilities 9 20 43 4
Adjusted EBITDA $ 1,355 $ 1,099 $ 3,821 $ 3,383
Net operating revenues $ 5,631 $ 5,289 $ 16,627 $ 15,783
Net income available to Tenet Healthcare Corporation common shareholders as a % of net operating revenues 17.8 % 6.5 % 15.2 % 6.6 %
Adjusted EBITDA as a % of net operating revenues (Adjusted EBITDA margin) 24.1 % 20.8 % 23.0 % 21.4 %
TENET HEALTHCARE CORPORATIONAdditional Supplemental Non-GAAP disclosuresTable #3 – Reconciliations of Net Cash Provided by Operating Activities toFree Cash Flow and Adjusted Free Cash Flow(Unaudited)
2026
(Dollars in millions) Q3 YTD
Net cash provided by operating activities $ 1,281 $ 3,507
Purchases of property and equipment (198 ) (546 )
Free cash flow $ 1,083 $ 2,961
Net cash used in investing activities $ (298 ) $ (818 )
Net cash used in financing activities $ (479 ) $ (2,898 )
Net cash provided by operating activities $ 1,281 $ 3,507
Less:
Payments for restructuring charges, acquisition-related costs, and litigation costs and settlements (19 ) (103 )
Cash received for contract termination — 540
Adjusted net cash provided by operating activities 1,300 3,070
Purchases of property and equipment (198 ) (546 )
Adjusted free cash flow $ 1,102 $ 2,524
2025
(Dollars in millions) Q3 YTD
Net cash provided by operating activities $ 1,058 $ 2,809
Purchases of property and equipment (280 ) (646 )
Free cash flow $ 778 $ 2,163
Net cash used in investing activities $ (385 ) $ (886 )
Net cash used in financing activities $ (323 ) $ (1,967 )
Net cash provided by operating activities $ 1,058 $ 2,809
Less:
Payments for restructuring charges, acquisition-related costs, and litigation costs and settlements (3 ) (84 )
Adjusted net cash provided by operating activities 1,061 2,893
Purchases of property and equipment (280 ) (646 )
Adjusted free cash flow $ 781 $ 2,247
TENET HEALTHCARE CORPORATIONAdditional Supplemental Non-GAAP disclosuresTable #4 – Reconciliations of Outlook Net Income Available to Tenet Healthcare Corporation Common Shareholders to Outlook Adjusted Net Income Available to Common Shareholders(Unaudited)
FY 2026
(Dollars in millions, except per share amounts) Low High
Net income available to Tenet Healthcare Corporation common shareholders $ 2,973 $ 3,078
Less:
Revenue from contract termination 1,650 1,650
Impairment and restructuring charges, acquisition-related costs, and litigation costs and settlements(1) (180 ) (150 )
Net gains on sales, consolidation and deconsolidation of facilities(2) 43 43
Loss from early extinguishment of debt(2) (5 ) (5 )
Tax and noncontrolling interests impact of above items (365 ) (370 )
Adjusted net income available to common shareholders $ 1,830 $ 1,910
Diluted earnings per share $ 35.82 $ 37.08
Less:
Revenue from contract termination 19.88 19.88
Impairment and restructuring charges, acquisition-related costs, and litigation costs and settlements (2.17 ) (1.81 )
Net gains on sales, consolidation and deconsolidation of facilities 0.52 0.52
Loss from early extinguishment of debt (0.06 ) (0.06 )
Tax and noncontrolling interests impact of above items (4.40 ) (4.46 )
Adjusted diluted earnings per share $ 22.05 $ 23.01
Weighted average dilutive shares outstanding (in thousands) 83,000 83,000
(1) The figures shown represent the Company's estimate for restructuring charges plus the actual year-to-date results for impairment and restructuring charges, acquisition-related costs, and litigation costs and settlements. The Company does not generally forecast impairment charges, acquisition-related costs, and litigation costs and settlements because it does not believe that it can forecast these items with sufficient accuracy since some of these items are indeterminable at the time the Company provides its financial Outlook.
(2) The Company does not generally forecast net gains (losses) on sales, consolidation and deconsolidation of facilities or gains (losses) from early extinguishment of debt because the Company does not believe that it can forecast these items with sufficient accuracy since it is indeterminable at the time the Company provides its financial Outlook. The figures shown relate to transactions that have already occurred in 2026.
TENET HEALTHCARE CORPORATIONAdditional Supplemental Non-GAAP disclosuresTable #5 – Reconciliations of Outlook Net Income Available to Tenet Healthcare Corporation Common Shareholders to Outlook Adjusted EBITDA(Unaudited)
FY 2026
(Dollars in millions) Low High
Net income available to Tenet Healthcare Corporation common shareholders $ 2,973 $ 3,078
Less:
Net income available to noncontrolling interests (910 ) (960 )
Income tax expense (1,135 ) (1,170 )
Interest expense (825 ) (815 )
Loss from early extinguishment of debt(2) (5 ) (5 )
Other non-operating income, net 150 200
Net gains on sales, consolidation and deconsolidation of facilities(2) 43 43
Impairment and restructuring charges, acquisition-related costs, and litigation costs and settlements(1) (180 ) (150 )
Depreciation and amortization (865 ) (915 )
Revenue from contract termination 1,650 1,650
Adjusted EBITDA $ 5,050 $ 5,200
Net income available to Tenet Healthcare Corporation common shareholders $ 2,973 $ 3,078
Net operating revenues $ 22,050 $ 22,450
Net income available to Tenet Healthcare Corporation common shareholders as a % of net operating revenues 13.5 % 13.7 %
Adjusted EBITDA as a % of net operating revenues (Adjusted EBITDA margin) 22.9 % 23.2 %
(1) The figures shown represent the Company's estimate for restructuring charges plus the actual year-to-date results for impairment and restructuring charges, acquisition-related costs, and litigation costs and settlements. The Company does not generally forecast impairment charges, acquisition-related costs, and litigation costs and settlements because it does not believe that it can forecast these items with sufficient accuracy since some of these items are indeterminable at the time the Company provides its financial Outlook.
(2) The Company does not generally forecast net gains (losses) on sales, consolidation and deconsolidation of facilities or gains (losses) from early extinguishment of debt because the Company does not believe that it can forecast these items with sufficient accuracy since it is indeterminable at the time the Company provides its financial Outlook. The figures shown relate to transactions that have already occurred in 2026.
TENET HEALTHCARE CORPORATIONAdditional Supplemental Non-GAAP disclosuresTable #6 – Reconciliations of Outlook Net Cash Provided by Operating Activitiesto Outlook Free Cash Flow and Outlook Adjusted Free Cash Flow(Unaudited)
FY 2026
(Dollars in millions) Low High
Net cash provided by operating activities $ 3,885 $ 4,315
Purchases of property and equipment (700 ) (800 )
Free cash flow $ 3,185 $ 3,515
Net cash provided by operating activities $ 3,885 $ 4,315
Less:
Payments for restructuring charges, acquisition-related costs and litigation costs and settlements(1) (180 ) (150 )
Cash received for contract termination 540 540
Adjusted net cash provided by operating activities 3,525 3,925
Purchases of property and equipment (700 ) (800 )
Adjusted free cash flow(2) $ 2,825 $ 3,125
(1) The figures shown represent the Company's estimate for restructuring payments plus the actual year-to-date payments for restructuring charges, acquisition-related costs, and litigation costs or settlements. The Company does not generally forecast payments for acquisition-related costs, and litigation costs and settlements because it does not believe that it can forecast these items with sufficient accuracy since some of these items are indeterminable at the time the Company provides its financial Outlook.
(2) The Company’s definition of Adjusted Free Cash Flow does not include other important uses of cash including (1) cash used to purchase businesses or joint venture interests, or (2) any items that are classified as Cash Flows From Financing Activities on the Company’s Consolidated Statement of Cash Flows, including items such as (i) cash used to repay borrowings, and (ii) distributions paid to noncontrolling interests.

Investor Contact
Will McDowell
469-893-2387
[email protected]

Media Contact
Olivia E. Nadler
469-893-6352
[email protected]

Source: Tenet Healthcare Corporation

Multimedia Files:

View all Press Releases

Email Alerts

To opt-in for investor email alerts, please enter your email address in the field below and select at least one alert option. After submitting your request, you will receive an activation email to the requested email address. You must click the activation link in order to complete your subscription. You can sign up for additional alert options at any time.

At Tenet Health, we promise to treat your data with respect and will not share your information with any third party. You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ section below. If you experience any issues with this process, please contact us for further assistance.

By providing your email address below, you are providing consent to Tenet Health to send you the requested Investor Email Alert updates.

Email Address * Mailing Lists *

Press Releases
Events
Presentations
SEC Filings

Unsubscribe

Captcha
Enter the code shown above.
*

Email Alert Sign Up Confirmation

Tenet Health Logo

© 2016-2026 TH Medical • All Rights Reserved

Powered By Q4 Inc. 5.191.0.1 (opens in new window)

script

October 2, 2026

DALLAS--(BUSINESS WIRE)-- Tenet Healthcare Corporation (NYSE: THC) will release its third quarter 2026 results before the market opens on Thursday, October 29, 2026, to be followed by a conference call at 9:00 a.m. CT (10:00 a.m. Eastern Time).

A live webcast and audio archive of the call may be accessed through the investor relations section of Tenet’s website at www.tenethealth.com/investors .

About Tenet Healthcare

Tenet Healthcare Corporation (NYSE: THC) is a diversified healthcare services company headquartered in Dallas. Our care delivery network includes United Surgical Partners International, the largest ambulatory platform in the country, which operates ambulatory surgery centers and surgical hospitals. We also operate a national portfolio of acute care and specialty hospitals, other outpatient facilities, a network of leading employed physicians and a global business center in Manila, Philippines. Our Conifer Health Solutions subsidiary provides revenue cycle management and value-based care services to hospitals, health systems, physician practices, employers, and other clients. Across the Tenet enterprise, we are united by our mission to deliver quality, compassionate care in the communities we serve. For more information, please visit www.tenethealth.com .

Investor Contact
Will McDowell
469-893-2387
[email protected]

Media Contact
Olivia E. Nadler
469-893-6352
[email protected]

Source: Tenet Healthcare Corporation

Multimedia Files:

View all Press Releases

Email Alerts

To opt-in for investor email alerts, please enter your email address in the field below and select at least one alert option. After submitting your request, you will receive an activation email to the requested email address. You must click the activation link in order to complete your subscription. You can sign up for additional alert options at any time.

At Tenet Health, we promise to treat your data with respect and will not share your information with any third party. You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ section below. If you experience any issues with this process, please contact us for further assistance.

By providing your email address below, you are providing consent to Tenet Health to send you the requested Investor Email Alert updates.

Email Address * Mailing Lists *

Press Releases
Events
Presentations
SEC Filings

Unsubscribe

Captcha
Enter the code shown above.
*

Email Alert Sign Up Confirmation

Tenet Health Logo

© 2016-2026 TH Medical • All Rights Reserved

Powered By Q4 Inc. 5.191.0.1 (opens in new window)

script

The information set forth below in Item 2.03 is incorporated by reference into this Item 1.01.

Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

On September 22, 2026, Tenet Healthcare Corporation (the “Company”) issued $2,000,000,000 in aggregate principal amount of 6.250% senior notes due 2034 (the “Notes”). The Notes were issued pursuant to an indenture, dated as of November 6, 2001 (the “Base Indenture”), between the Company and The Bank of New York Mellon Trust Company, N.A., as successor trustee to The Bank of New York as trustee (in such capacity, the “Trustee”), as supplemented by the forty-third supplemental indenture, dated as of September 22, 2026, between the Company and the Trustee (the “Forty-Third Supplemental Indenture” and, the Base Indenture, as supplemented by the Forty-Third Supplemental Indenture, the “Indenture”).

Prompts

Tenet Healthcare Corporation (ticker THC), listed in United States.

Company History

Date Change Detail
Oct 1, 2013 Acquired Acquired Vanguard Health Systems Inc (CIK 1045829). Its filings from before the deal are on its own company page, not shown here.

ETFs Holding Tenet Healthcare Corporation

ETF Weight in ETF Shares Market value As of
BCUS 3.21% 16,325 $ 4.683M Nov 12, 2026
BASV 2.79% 60,976 $ 11.407M Jun 30, 2026
LYLD 2.56% 728 $ 185.48K Jul 31, 2026
ARWG 2.55% 1,417 $ 376.794K Aug 31, 2026
AMID 2.26% 9,288 $ 2.62M Nov 18, 2026
SMRI 2.14% 52,905 $ 14.92M Nov 18, 2026
QVAL 2.05% 52,939 $ 14.93M Nov 18, 2026
ECML 1.81% 7,717 $ 2.18M Nov 18, 2026
ABCS 1.70% 798 $ 212.196K Aug 31, 2026
SYLD 1.32% 51,569 $ 13.139M Jul 31, 2026
TAX 1.32% 1,263 $ 335.844K Aug 31, 2026
SMDX 1.27% 5,519 $ 1.609M Nov 17, 2026
ROE 1.14% 9,980 $ 2.82M Nov 18, 2026
LSEQ 1.10% 635 $ 181.629K Nov 13, 2026
PSTR 1.07% 2,719 $ 723.009K Aug 31, 2026
SURE 1.04% 2,112 $ 595.732K Nov 17, 2026
SEIV 0.98% 76,690 $ 14.347M Jun 30, 2026
DVAL 0.91% 3,525 $ 659.457K Jun 30, 2026
TMSL 0.89% 128,610 $ 24.06M Jun 30, 2026
GQQQ 0.79% 4,625 $ 1.3M Nov 18, 2026
GDMA 0.76% 5,052 $ 1.43M Nov 18, 2026
CGMM 0.71% 87,650 $ 25.553M Nov 16, 2026
FEMV 0.64% 180 $ 33.674K Jun 30, 2026
TIME 0.59% 300 $ 87.462K Nov 17, 2026
TMED 0.56% 693 $ 129.646K Jun 30, 2026
FFSM 0.46% 26,845 $ 6.84M Jul 31, 2026
JMEE 0.45% 46,076 $ 12.997M Nov 17, 2026
MSSM 0.44% 11,768 $ 3.129M Aug 31, 2026
EHLS 0.42% 775 $ 225.944K Nov 17, 2026
DSTL 0.39% 44,049 $ 8.241M Jun 30, 2026
FLDZ 0.37% 81 $ 15.153K Jun 30, 2026
REMC 0.37% 66 $ 12.347K Jun 30, 2026
EBI 0.35% 9,044 $ 2.405M Aug 31, 2026
TVAL 0.32% 12,419 $ 3.621M Nov 17, 2026
AVMC 0.26% 4,921 $ 1.435M Nov 16, 2026
CDX short -0.24% -2,120.4024 $ -598.102K Nov 17, 2026
DFLV 0.18% 47,055 $ 13.498M Nov 12, 2026
TACU 0.17% 105 $ 30.612K Nov 17, 2026
DFUV 0.14% 77,478 $ 22.225M Nov 12, 2026
AFMC 0.14% 1,247 $ 363.55K Nov 16, 2026
FTLS 0.13% 11,901 $ 0.00 Nov 16, 2026
NBCR 0.13% 4,062 $ 1.08M Aug 31, 2026
GVLU 0.11% 1,013 $ 295.33K Nov 17, 2026
FELV 0.11% 17,978 $ 3.363M Jun 30, 2026
DFVX 0.10% 2,098 $ 601.832K Nov 12, 2026
DFAC 0.10% 312,048 $ 89.514M Nov 12, 2026
THRO 0.10% 36,127 $ 10.532M Nov 16, 2026
DXUV 0.09% 20,081 $ 5.76M Nov 12, 2026
DCOR 0.09% 143,865 $ 41.269M Nov 12, 2026
VFVA 0.09% 3,250 $ 864.208K Aug 31, 2026
FMDE 0.07% 27,825 $ 5.206M Jun 30, 2026
IALT 0.07% 18,048 $ 5.262M Nov 16, 2026
FELC 0.07% 27,416 $ 5.129M Jun 30, 2026
VSLU 0.06% 1,784 $ 333.751K Jun 30, 2026
ENHU 0.05% 17 $ 4,956.18 Nov 16, 2026
DFAU 0.05% 22,308 $ 6.399M Nov 12, 2026
DFUS 0.03% 26,176 $ 7.509M Nov 12, 2026
MODL 0.03% 1,860 $ 347.969K Jun 30, 2026
DUHP 0.03% 22,817 $ 6.545M Nov 12, 2026
AVLC 0.03% 1,520 $ 443.141K Nov 16, 2026
MSLC 0.02% 3,505 $ 932.015K Aug 31, 2026
GDE 0.02% 382 $ 101.578K Aug 31, 2026
NTSD 0.02% 40 $ 7,483.20 Jun 30, 2026
DYNF 0.02% 22,282 $ 6.496M Nov 16, 2026
NTSX 0.01% 914 $ 170.991K Jun 30, 2026
AVUS 0.01% 3,716 $ 1.083M Nov 16, 2026
AVSU 0.01% 141 $ 41.107K Nov 16, 2026
DFSU 0.00% 47 $ 13.482K Nov 12, 2026
FHEQ 0.00% 3 $ 764.34 Jul 31, 2026